Hyperoxaluria, Primary clinical trials
The registry lists 42 studies for Hyperoxaluria, Primary across more than 10 countries. 11 are recruiting or about to start. 26 of them are mainly about Hyperoxaluria, Primary (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-19. Counting its narrower condition Primary hyperoxaluria type 1 too: 52 studies, 14 open.
Get an email when these change. Save the Hyperoxaluria, Primary studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Mayo Clinic (10) · Alnylam Pharmaceuticals (6) · OxThera (6) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (5) · YolTech Therapeutics Co., Ltd (2) · Biocodex (2) · University of Cologne (1) · UK Kidney Association (1)
What is being tested here
Drugs under test in Hyperoxaluria, Primary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Jul 2027Follow-up of Pediatric Patients Affected by Primary Hyperoxaluria Type 1 (PH1) Treated With Lumasiran · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Aug 2027Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1) · YolTech Therapeutics Co., Ltd
- Oct 2027Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1) · YolTech Therapeutics Co., Ltd
Who these studies take
Of the 9 Hyperoxaluria, Primary studies recruiting now, 6 (67%) set no upper age limit and 2 (22%) stop at 75 or younger. 9 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 8 (89%) | 8 (89%) |
| 18 | 8 (89%) | 8 (89%) |
| 30 | 8 (89%) | 8 (89%) |
| 40 | 8 (89%) | 8 (89%) |
| 50 | 8 (89%) | 8 (89%) |
| 65 | 7 (78%) | 7 (78%) |
| 75 | 7 (78%) | 7 (78%) |
| 85 | 7 (78%) | 7 (78%) |
Across all 42 studies, recruiting or not: 24% stop at 75 or younger and 21% at 65; 98% take children; 0% are for women only and 0% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 11, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 42 of 42. search them.
- Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)RecruitingNCT06839235Phase 1/25 countries
- Follow-up of Pediatric Patients Affected by Primary Hyperoxaluria Type 1 (PH1) Treated With LumasiranEnrolling by invitationNCT078740741 country
- Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)RecruitingNCT07587021Phase 21 country
- Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1)RecruitingNCT07776626Phase 11 country
- Prospective Research Rare Kidney Stones (ProRKS)RecruitingNCT027802974 countries
- Rare Kidney Stone Consortium BiobankRecruitingNCT020263881 country
- Rare Kidney Stone Consortium Patient RegistryRecruitingNCT005885622 countries
- Monogenic Kidney Stone - Genetic TestingRecruitingNCT033058351 country
- Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3Not yet recruitingNCT06465472Phase 3
- National Registry of Rare Kidney DiseasesRecruitingNCT060658521 country
- Genetic Newborn Screening for Cystinosis and Primary HyperoxaluriaRecruitingNCT05843851Not applicable1 country
- Long Term Extension Study in Patients With Primary HyperoxaluriaActive, not recruitingNCT04042402Phase 313 countries
- Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal FunctionCompletedNCT05001269Phase 211 countries
- Baby Detect : Genomic Newborn ScreeningCompletedNCT056874741 country
- A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1CompletedNCT04152200Phase 311 countries
- A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1CompletedNCT03905694Phase 35 countries
- Natural History of Patients With PH3 and a History of Stone EventsCompletedNCT045425905 countries
- Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary HyperoxaluriaCompletedNCT03392896Phase 15 countries
- Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 PatientsCompletedNCT04555486Phase 14 countries
- A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1CompletedNCT03681184Phase 38 countries
- A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2CompletedNCT03847909Phase 215 countries
- An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1CompletedNCT03350451Phase 25 countries
- Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1Approved for marketingNCT04125472
- Health-related Quality of Life in Rare Kidney StoneCompletedNCT021243952 countries
- Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on DialysisCompletedNCT02000219Phase 21 country
- A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary HyperoxaluriaCompletedNCT03116685Phase 37 countries
- An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary HyperoxaluriaTerminatedNCT03938272Phase 36 countries
- Phenotyping of Primary HyperoxaluriaStatus unknownNCT051078301 country
- Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary HyperoxaluriaCompletedNCT03819647Phase 21 country
- Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and HyperoxalemiaCompletedNCT03391804Phase 23 countries
- Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1CompletedNCT02706886Phase 1/25 countries
- Primary Hyperoxaluria Mutation Genotyping/PhenotypingCompletedNCT023406891 country
- Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric PatientsStatus unknownNCT027946491 country
- Hydroxyproline Influence on Oxalate MetabolismCompletedNCT02038543Phase 1/21 country
- Primary Hyperoxaluria Mutation GenotypingCompletedNCT005892251 country
- Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary HyperoxaluriaCompletedNCT02012985Phase 1/23 countries
- International Registry for Primary HyperoxaluriaWithdrawnNCT008758231 country
- Renal Protective Effect of ACEI and ARB in Primary HyperoxaluriaWithdrawnNCT00280215Phase 3
- Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary HyperoxaluriaCompletedNCT00283387Phase 21 country
- Phase 2/3 Oxabact StudyCompletedNCT01037231Phase 2/33 countries
- Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria PatientsCompletedNCT00638703Phase 2/31 country
- Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphateCompletedNCT01281878Phase 21 country